Hizentra Market Report 2026

Hizentra Market Overview

• The Hizentra market growth in the historic period has been driven by limitations of ivig hospital based therapy, increasing prevalence of primary immunodeficiency • Market expansion is supported by growth in home healthcare services, increasing diagnosis of immune disorders • Growth Driver: Escalating Autoimmune Disorders Fueling Growth In The Market • Market Trend: Innovative Product Development And Prefilled Syringes Boosting Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hizentra Market?

Hizentra is a brand of subcutaneous immunoglobulin (SCIg) therapy used to treat patients with primary immunodeficiencies, such as common variable immunodeficiency (CVID), and certain other immune-related conditions. It contains immunoglobulin G (IgG), a protein that helps the immune system fight infections. Hizentra is administered under the skin (subcutaneously), providing an alternative to intravenous immunoglobulin (IVIg) therapy, and is typically used to boost the body’s immune defense in individuals whose immune systems are compromised. The medication is known for its ability to offer more flexible dosing and potentially improved convenience compared to traditional IV-based therapies. The main product types of hizentra are subcutaneous immunoglobulin (SCIg) and intravenous immunoglobulin (IVIg). Subcutaneous immunoglobulin (SCIg) is a form of immunoglobulin therapy that is administered under the skin to help boost the immune system in patients with immune deficiencies. It is used for primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CDIP) and is distributed through various channels including hospitals, specialty pharmacies, home healthcare providers, and retail pharmacies.

What Is The Hizentra Market Growth Forecast?

The growth in the forecast period can be attributed to growth in home healthcare services, increasing diagnosis of immune disorders, expansion of long term replacement therapy demand, technological advances in infusion devices, supportive reimbursement for scig. Major trends in the forecast period include shift toward subcutaneous immunoglobulin therapy, growth of home based immunodeficiency treatment, preference for flexible and self administered dosing, expansion of long term immunoglobulin replacement, rising focus on patient quality of life.

Global Hizentra Market Segmentation

1) By Product Type: Subcutaneous Immunoglobulin (SCIg), Intravenous Immunoglobulin (IVIg) 2) By Indication: Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 3) By Distribution Channel: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Retail Pharmacies

What Are The Drivers Of The Hizentra Market?

The rising autoimmune disorders are expected to accelerate the hizentra market. Autoimmune disorders are conditions where the immune system mistakenly attacks the body's own healthy cells, tissues, or organs. Autoimmune disorders are rising due to a combination of genetic, environmental, and lifestyle factors, including an increase in environmental toxins, dietary changes, and reduced exposure to pathogens. Hizentra is used in autoimmune disorders to provide immunoglobulin replacement therapy, helping regulate immune system activity and reduce disease symptoms. For instance, in May 2023, according to the NIHR Imperial Biomedical Research Centre, a UK-based government research institute and agency, the study analyzed anonymized electronic health records from 22 million UK individuals to examine 19 common autoimmune diseases, which affect roughly 10% of the population-13% of women and 7% of men. Therefore, the rise in autoimmune disorders is driving the hizentra industry. The increasing healthcare expenditure is expected to propel the growth of the hizentra market going forward. Healthcare expenditure refers to the total amount of resources spent on healthcare services, products, and related activities, including prevention, diagnosis, treatment, and management of health conditions. Healthcare expenditure is rising due to factors such as an aging population, advancements in medical technology, increasing prevalence of chronic diseases, and higher costs of pharmaceuticals and medical services. Increased healthcare expenditure enhances the accessibility and affordability of Hizentra, supporting the treatment of patients with primary immunodeficiency and other conditions. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the hizentra industry.

Key Players In The Global Hizentra Market

Major companies operating in the hizentra market are CSL Behring

Global Hizentra Market Trends and Insights

The key trend in the hizentra market is focusing on developing innovative products, such as prefilled syringes, to gain a competitive edge in the industry. A prefilled syringe is a single-use device that comes prefilled with a specific dose of medication, ensuring accurate dosing and reducing preparation time. Typically made of glass or plastic, these syringes are designed for ease of use in self-administration or in clinical settings. For instance, in April 2023, CSL Behring, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved a new 50 mL/10 g prefilled syringe for Hizentra (immune globulin subcutaneous [human] 20% Liquid). With this addition, CSL Behring now offers a complete range of prefilled syringe sizes tailored to the unique needs of individuals with primary immunodeficiency (PI) or chronic inflammatory demyelinating polyneuropathy (CIDP). Hizentra is the first and only immune globulin (Ig) available in an easy-to-use, ready-to-administer prefilled syringe format.

Regional Insights

North America was the largest region in the hizentra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Hizentra Market?

The hizentra market consists of sales of coagulation factor concentrates, albumin solutions, hyperimmune immunoglobulins, and cryoprecipitate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hizentra Market Report 2026?

The hizentra market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hizentra industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.